

Prostate Cancer Treatment Pathways

Patient Name: _____ Date of Birth: _____

Member ID: _____ Treatment Start Date: _____

Stage: _____ Pathology: _____

ECOG Status: 1 2 3 4 ICD-10 Code: _____

Line of Therapy:

Neoadjuvant/Pre-op Adjuvant/Post Op 1st Line 2nd Line 3rd Line 3rd Line+ Maintenance

Biomarkers/Attributes: (select all that apply)

Micro-satellite Instability:	<input type="checkbox"/> d-MMR/MSI-H	<input type="checkbox"/> MSI-L	<input type="checkbox"/> Not Reported	BRCA ½:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported
PD-L1:	<input type="checkbox"/> 1 – 49%	<input type="checkbox"/> ≥ 50%	<input type="checkbox"/> Negative	HRRm mutations:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported
	<input type="checkbox"/> Not Reported			HRRm include: BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, RAD51B/51C/51D/45L			
TMB > 10 mut/Mb:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported	Visceral Mets:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported
Small cell:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported	Bone Mets:	<input type="checkbox"/> Absent	<input type="checkbox"/> Present	<input type="checkbox"/> Not Reported
Continue androgen deprivation therapy: (select medication below if applicable)				<input type="checkbox"/> YES	<input type="checkbox"/> NO	<input type="checkbox"/> Patient had orchiectomy	

Androgen Deprivation Therapy (ADT)

- Goserelin
- Leuprolide
- Triptorelin
- Degarelix
- Bicalutamide + LHRH agonist (goserelin, leuprolide, triptorelin)

Adjuvant/ Neoadjuvant / Localized Disease

- ADT as above
- ADT + Abiraterone + Prednisone (very high risk)
- ADT + Docetaxel + Prednisone (very high risk)

Regional Disease (Hormone Naïve)

- ADT as above
- ADT + Abiraterone + Prednisone

Metastatic Castration/Hormone Naïve

- ADT as above
- ADT + Docetaxel + Prednisone
- ADT + Abiraterone + Prednisone
- ADT + Apalutamide
- ADT + Enzalutamide

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.



Nonmetastatic Castration/Hormone Resistant

- ADT as above
- ADT + Apalutamide
- ADT + Darolutamide
- ADT + Enzalutamide

Metastatic Castration/ Hormone Resistant First Line

- ADT as above
- ADT +/- Docetaxel + Prednisone
- ADT +/- Abiraterone + Prednisone
- ADT +/- Enzalutamide

Metastatic Castration/Hormone Resistant Second Line and Subsequent therapy

- ADT as above
- ADT +/- Docetaxel + Prednisone (if not previously given)
- ADT +/- Abiraterone + Prednisone or Dexamethasone
- ADT +/- Enzalutamide
- ADT +/- Cabazitaxel + Prednisone
- ADT +/- Mitoxantrone + Prednisone

Metastatic Small Cell Prostate

- Carboplatin + Etoposide
- Cisplatin + Etoposide

References:

Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. *J Clin Oncol*. 2014;32(30):3436-3448. doi:10.1200/JCO.2013.54.8404

National Comprehensive Cancer Network. Hematopoietic Growth Factors (Version 4.2021). https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf

National Comprehensive Cancer Network. Prostate Cancer (Version 1.2022). https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf

Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2020;31(9):1119-1134. doi:10.1016/j.annonc.2020.06.011

Schaeffer, Srinivas, et al. Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines. *J Natl Compr Canc Netw*. 2021; 19(2):134-143. doi: 10.6004/jnccn.2021.0008

Virgo KS, Basch E, Loblaw DA, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion [published correction appears in *J Clin Oncol*. 2017 Aug 1;35(22):2591] [published correction appears in *J Clin Oncol*. 2017 Dec 20;35(36):4096]. *J Clin Oncol*. 2017;35(17):1952-1964. doi:10.1200/JCO.2017.72.8030

Virgo KS, Rumble RB, de Wit R, et al. Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. *J Clin Oncol*. 2021;39(11):1274-1305. doi:10.1200/JCO.20.03256

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Abida W, Patnaik A, Campbell D, et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. *J Clin Oncol.* 2020;38(32):3763-3772. doi:10.1200/JCO.20.01035

Antonarakis ES, Piulats JM, Gross-Goupil M, et al. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. *J Clin Oncol.* 2020;38(5):395-405. doi:10.1200/JCO.19.0163

Aparicio AM, Harzstark AL, Corn PG, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. *Clin Cancer Res.* 2013;19(13):3621-3630. doi:10.1158/1078-0432.CCR-12-3791

Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. *J Clin Oncol.* 2019;37(32):2974-2986. doi:10.1200/JCO.19.00799

Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med.* 2014;371(5):424-433. doi:10.1056/NEJMoa1405095

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. *J Clin Oncol.* 2008;26(2):242-245. doi:10.1200/JCO.2007.12.4008

Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. *J Clin Oncol.* 2008;26(2):242-245. doi:10.1200/JCO.2007.12.4008

Bouman-Wammes EW, van den Berg HP, de Munck L, et al. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. *Eur J Cancer.* 2018;90:1-9. doi:10.1016/j.ejca.2017.11.021

"Chi KN, Agarwal N, Bjartell A, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. *N Engl J Med.* 2019;381(1):13-24. doi:10.1056/NEJMoa1903307

DOI: 10.1200/JCO.2021.39.6_suppl.11 *Journal of Clinical Oncology* 39, no. 6_suppl (February 20, 2021) 11-11."

Corn PG, Heath EI, Zurita A, et al. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial [published correction appears in *Lancet Oncol.* 2020 Jan;21(1):e14]. *Lancet Oncol.* 2019;20(10):1432-1443. doi:10.1016/S1470-2045(19)30408-5

Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. *J Urol.* 2011;186(3):889-897. doi:10.1016/j.juro.2011.04.083

de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. *N Engl J Med.* 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet.* 2010;376(9747):1147-1154. doi:10.1016/S0140-6736(10)61389-X

de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. *Lancet.* 2010;376(9747):1147-1154. doi:10.1016/S0140-6736(10)61389-X

de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. *N Engl J Med.* 2019;381(26):2506-2518. doi:10.1056/NEJMoa1911206

Fenioux C, Louvet C, Charton E, et al. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. *BJU Int.* 2019;123(2):300-306. doi:10.1111/bju.14511

Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study [published correction appears in *Lancet Oncol.* 2012 Nov;13(11):e464] [published correction appears in *Lancet Oncol.* 2014 Aug;15(9):e365]. *Lancet Oncol.* 2012;13(10):983-992. doi:10.1016/S1470-2045(12)70379-0

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2019;380(13):1235-1246. doi:10.1056/NEJMoa1815671

Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. *N Engl J Med*. 2020;383(11):1040-1049. doi:10.1056/NEJMoa2001342

Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N Engl J Med*. 2018;378(26):2465-2474. doi:10.1056/NEJMoa1800536

James ND, de Bono JS, Spears MR, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. *N Engl J Med*. 2017;377(4):338-351. doi:10.1056/NEJMoa1702900

James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. *Lancet*. 2016;387(10024):1163-1177. doi:10.1016/S0140-6736(15)01037-5

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med*. 2010;363(5):411-422. doi:10.1056/NEJMoa1001294

Loriot Y, Massard C, Gross-Goupil M, et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. *Ann Oncol*. 2009;20(4):703-708.

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med*. 2013;369(3):213-223. doi:10.1056/NEJMoa1213755

Schellhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. *Urology*. 2013;81(6):1297-1302. doi:10.1016/j.urology.2013.01.061

Schellhammer PF, Sharifi R, Block NL, et al. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. *Urology*. 1997;50(3):330-336. doi:10.1016/s0090-4295(97)00279-3

Schlegel PN; Histrelin Study Group. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. *J Urol*. 2006;175(4):1353-1358. doi:10.1016/S0022-5347(05)00649-X

Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. *N Engl J Med*. 2017;376(5):417-428. doi:10.1056/NEJMoa1607529

Shore ND, Saad F, Cookson MS, et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. *N Engl J Med*. 2020;382(23):2187-2196. doi:10.1056/NEJMoa2004325

Smith MR, Saad F, Chowdhury S, et al. Apalutamide and Overall Survival in Prostate Cancer. *Eur Urol*. 2021;79(1):150-158. doi:10.1016/j.eururo.2020.08.011

Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med*. 2018;378(15):1408-1418. doi:10.1056/NEJMoa1715546

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med*. 2015;373(8):737-746. doi:10.1056/NEJMoa1503747

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*. 2004;351(15):1502-1512. doi:10.1056/NEJMoa040720

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. *N Engl J Med*. 2004;351(15):1502-1512. doi:10.1056/NEJMoa040720

Note: Pathways are independent of specific OptumCare/health plan medical policy coverage criteria. OptumCare/health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered. Biosimilars or alternate formulations (along with the reference products) are considered on pathway unless otherwise specified by OptumCare/health plan formularies, medical policies, or preferred product rules.

Last Review [2.22.2022] | Effective [03.1.2022]/ *slf*